Why Patterson Companies Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Portfolio Pulse from Lisa Levin
Patterson Companies, Inc. (PDCO) shares fell by 14% after reporting Q2 earnings of $0.50 per share, missing estimates of $0.58 per share, and lowering FY24 adjusted EPS guidance below expectations. The company's sales were $1.65 billion, below the expected $1.70 billion. Other stocks moved in the mid-day session with various companies experiencing significant gains or losses due to various factors such as FDA clearances, earnings reports, acquisition announcements, and public offerings.
November 29, 2023 | 7:02 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Patterson Companies reported lower than expected Q2 earnings and reduced FY24 EPS guidance, causing a 14% drop in stock price.
The earnings miss and lowered guidance are critical factors that directly affect investor sentiment and the company's valuation, leading to a negative short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100
NEGATIVE IMPACT
Petco's stock fell 23.6% after reporting worse-than-expected Q3 financial results and lowering FY23 adjusted EPS guidance.
Negative earnings reports and reduced future earnings guidance can lead to a decline in stock price due to lowered investor expectations.
CONFIDENCE 85
IMPORTANCE 85
RELEVANCE 90
POSITIVE IMPACT
Foot Locker shares increased by 18% following the report of better-than-expected third-quarter financial results.
Positive earnings reports can lead to an increase in investor confidence and stock price, reflecting a positive short-term impact.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 80
POSITIVE IMPACT
Rover Group's stock rose 28.4% after announcing it will be acquired by Blackstone in a $2.3 billion transaction.
Acquisition news typically leads to a positive short-term reaction in the stock market as it often comes with a premium on the current stock price.
CONFIDENCE 85
IMPORTANCE 85
RELEVANCE 90
POSITIVE IMPACT
Vivos Therapeutics shares surged 135.2% after receiving FDA 510(k) clearance for an oral device treatment of severe obstructive sleep apnea.
FDA clearances can significantly boost a company's prospects by allowing them to market new treatments, leading to a positive short-term impact on the stock.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 90